Research Methodology and Epidemiology of Relevance in Recurrent Pregnancy Loss

ABSTRACT

With respect to recurrent pregnancy loss (RPL), unfortunately there is very little consensus about which investigations are useful for identifying causes and evaluating the prognosis, and also about which treatments are effective. In this review, arguments are given for the claim that this lack of consensus may mainly be because studies in the field of RPL have yielded very heterogeneous results. This heterogeneity, in the authors' belief, is caused by the scientists' lack of appreciation, when they do research, of important epidemiological knowledge about RPL (e.g., about the multifactorial background for most of the RPL cases and the importance of matching/adjusting for a series of prognostic variables when groups are mutually compared). Furthermore, many studies in RPL contain methodological flaws that are sometimes severe. A series of important epidemiological features of RPL is highlighted in the review and the most important methodological pitfalls, many of them specific for RPL research, are discussed. Advice is given about to how to avoid the pitfalls in order that the validity of the studies can improve for the benefit of the patients.

Abortion - epidemiology - pregnancy - recurrent miscarriage - research

REFERENCES

• 1 Beer A E, Quebbeman J F, Ayers J WT, Hainies R F. Major histocompatibility complex antigens, maternal and paternal immune responses, and chronic habitual abortions in humans.  Am J Obstet Gynecol. 1981;  141 987-999
• 2 Unander A M, Norberg R, Hahn L, Årfors L. Anticardiolipin antibodies and complement in ninety-nine women with habituals abortion.  Am J Obstet Gynecol. 1987;  156 114-119
• 3 Reznikof-Etievant M F, Cayol V, Carbonne B, Robert A, Coulet F, Milliez J. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage.  BJOG. 2001;  108 1251-1254
• 4 Aoki K, Kajiura S, Matsumoto Y et al.. Preconceptional natural killer cell activity as a predictor of miscarriage.  Lancet. 1995;  345 1340-1342
• 5 Pfeiffer K A, Fimmers R, Engels G, van der Ven H, van der Ven K. The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion.  Mol Hum Reprod. 2001;  7 373-378
• 6 Piccinni M, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions.  Nat Med. 1998;  4 1020-1023
• 7 Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A. Prevalence of genetic markers for thrombophilia in recurent pregancy loss.  Hum Reprod. 2002;  17 1633-1637
• 8 Sarig G, Younis J S, Hoffman R, Lanir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage.  Fertil Steril. 2002;  77 342-347
• 9 Grandone E, Margaglione M, Colaizzo D et al.. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses.  Thromb Haemost. 1997;  77 822-824
• 10 van Dunné F M, Doggen C JM, Heemskerk M, Rosendaal F R, Helmerhorst F M. Factor V Leiden mutation in relation to fecundity and miscarriage in women with venous thrombosis.  Hum Reprod. 2005;  20 802-806
• 11 Ober C, Karrison T, Odem R R et al.. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial.  Lancet. 1999;  354 365-369
• 12 Mowbray J F, Gibbings C, Liddell H et al.. Controlled trial of treatment of recurrent spontaneous abortions by immunization with paternal cells.  Lancet. 1985;  I 941-943
• 13 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low dose aspirin is superior to low dose aspirin alone.  Am J Obstet Gynecol. 1996;  174 1584-1589
• 14 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin plus heparin in pregnant women with recurring miscarriage associated with antiphospholipid antibodies.  BMJ. 1997;  314 253-257
• 15 Farquharson R G, Quenby S, Greaves M. Antiphosphlipid syndrome in pregnancy: a randomized, controlled trial of treatment.  Obstet Gynecol. 2002;  100 408-413
• 16 Nybo Andersen A M, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study.  BMJ. 2000;  320 1708-1712
• 17 Cauchi M N, Coulam C B, Cowscock S et al.. Predictive factors in recurrent spontaneous aborters-A multicenter study.  Am J Reprod Immunol. 1995;  33 165-170
• 18 Wramsby M L, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation.  Fertil Steril. 2000;  74 987-991
• 19 Christiansen O B, Pedersen B, Rosgaard A, Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage.  Hum Reprod. 2002;  17 809-816
• 20 Alexander S A, Latinne D, Debruyere M, Dupont E, Gottlieb W, Thomas K. Belgian experience with repeat immunization in recurrent spontaneous abortions. In: Beard RM, Sharp F Early Pregnancy Loss: Mechanisms and Treatment. London; Springer Verlag 1988: 355-363
• 21 Christiansen O B, Mathiesen O, Lauritsen J G, Grunnet N. Idiopathic recurrent spontaneous abortion. Evidence of a familial predisposition.  Acta Obstet Gynecol Scand. 1990;  69 597-601
• 22 Ho H, Gill T J, Hsieh C, Yang Y, Lee T. The prevalence of recurrent spontaneous abortions, cancer, and congenital anomalies in the families of couples with recurrent spontaneous abortions or gestational trophoblastic tumors.  Am J Obstet Gynecol. 1991;  165 461-466
• 23 Emery A EH. Methodology in Medical Genetics. Edinburgh, United Kingdom; Churchill Livingstone 1986
• 24 Christiansen O B, Andersen H H, Hojbjerre M, Kruse T A, Lauritzen S L, Grunnet N. Maternal HLA class II allogentypes are markers for the predisposition to fetal losses in families of women with unexplained recurrent fetal loss.  Eur J Immunogenet. 1995;  22 323-334
• 25 Axelsson G, Rylander R. Validation of questionnaire reported miscarriage, malformation and birth weight.  Int J Epidemiol. 1984;  13 94-98
• 26 Wilcox A J, Horney L F. Accuracy of spontaneous abortion recall.  Am J Epidemiol. 1984;  120 727-733
• 27 Coulam C B, Krysa L, Stern J J, Bustillo M. Intravenous immnoglobulin for treatment of recurrent pregnancy loss.  Am J Reprod Immunol. 1995;  34 333-337
• 28 Kruse C, Rosgaard A, Steffensen R, Varming K, Jensenius J C, Christiansen O B. Low serum level of mannan-binding lectin is a determinant for pregnancy outcome in women with recurrent spontaneous abortion.  Am J Obstet Gynecol. 2002;  187 1313-1320
• 29 Creasy R. The cytogenetics of spontaneous abortion in humans. In: Beard RW, Sharp F Early Pregnancy Loss: Mechanisms and Treatment. London; Springer Verlag 1988: 293-304
• 30 Christiansen O B. A fresh look at the causes and treatments of recurrent miscarriage, especially its immunological aspects.  Hum Reprod Update. 1996;  2 271-293
• 31 Ogasawara M, Aoki K, Okada S et al.. Embryonic karyotype of abortuses in relation to the number of previous miscarriages.  Fertil Steril. 2000;  73 300-304
• 32 Out H J, Bruinse H W, Christiaens G C et al.. Prevalence of antiphospholipid antibodies in patients with fetal loss.  Ann Rheum Dis. 1991;  50 533-557
• 33 Byrd J R, Askew D E, McDonough P G. Cytogenetic findings in fifty-five couples with recurrent fetal wastage.  Fertil Steril. 1977;  28 246-250
• 34 Christiansen O B, Rasmussen K L, Jersild C, Grunnet N. HLA class II alleles confer susceptibility to recurrent fetal losses in Danish women.  Tissue Antigens. 1994;  44 225-233
• 35 Coulam C B. Immunological tests in the evaluation of reproductive disorders: a critical review.  Am J Obstet Gynecol. 1992;  167 1844-1851
• 36 Ailus K T. A follow-up study of immunoglobulin levels and autoantibodies in an unselected pregnant population.  Am J Reprod Immunol. 1994;  31 189-196
• 37 Topping J, Quenby S, Farquharson R, Malia R, Greaves M. Marked variation in antiphospholid antibodies during pregnancy: relationships to pregnancy outcome.  Hum Reprod. 1999;  14 224-228
• 38 Makhseed M, Raghupathy R, Azizieh F, Omu A, Al-Shamali E, Ashkanani L. Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions.  Hum Reprod. 2001;  16 2219-2226
• 39 Birkeland S A, Kristoffersen K. The fetus as an allograft: a longitudinal study of normal human pregnancies studied with mixed lymphocyte cultures between mother-father and mother-child.  Scand J Immunol. 1980;  11 311-319
• 40 Birkeland S A, Kristoffersen K. Lymphocyte transformation with mitogens and antigens during normal human pregnancy: a longitudinal study.  Scand J Immunol. 1980;  11 321-325
• 41 Michel M, Clark D A, Mowbray J F, Beard R W. Histologic and immunologic study of uterine biopsy tissue of women with incipient abortion.  Am J Obstet Gynecol. 1989;  161 409-414
• 42 Yamamoto T, Takahashi Y, Kase N, Mori H. Decidual natural killer cells in recurrent spontaneous abortion with normal chromosomal content.  Am J Reprod Immunol. 1999;  41 337-342
• 43 Piccinni M-P, Giudizi M G, Biagiotti R et al.. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones.  J Immunol. 1995;  155 128-133
• 44 Szekeres-Bartho J, Faust Z, Varga P et al.. The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production.  Am J Reprod Immunol. 1996;  35 348-351
• 45 Bradford-Hill A. The environment and disease: association or causation?.  Proc R Soc Med. 1965;  9 295-300
• 46 Jablonowska B, Selbing A, Palfi M, Ernerudh J, Kjellberg S, Lindton B. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study.  Hum Reprod. 1999;  14 838-841
• 47 Malpas P. A study of abortion sequences.  J Obstet Gynaecol Br Empire. 1938;  45 932-949
• 48 Rai R S, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies.  Hum Reprod. 1995;  10 3301-3304
• 49 Out H J, Bruinse H W, Christiaens G CML et al.. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies.  Am J Obstet Gynecol. 1992;  167 26-32
• 50 Nielsen H S, Christiansen O B. Prognostic impact of anticardiolipin antibodies in women with recurrent miscarriage negative for the lupus anticoagulant.  Hum Reprod. 2005;  20 1720-1728
• 51 Gibb D MF, Salari D A. Transabdominal cervicoistmic cerclage in the management of recurrent second trimester miscarriage and preterm delivery.  Br J Obstet Gynaecol. 1995;  102 802-806
• 52 Yudkin P L, Stratton I M. How to deal with regression to the mean in intervention studies.  Lancet. 1996;  347 241-243
• 53 Christiansen O B. Transabdominal cervicoistmic cerclage in the management of recurrent second trimester miscarriage and preterm delivery [comment].  Br J Obstet Gynaecol. 1996;  103 595-596
• 54 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.  Thromb Haemost. 2000;  83 693-697
• 55 Grandone E, Brancaccio V, Colaizzo D et al.. Preventing adverse obsteric outcomes in women with genetic thrombophilia.  Fertil Steril. 2002;  78 371-375
• 56 Reznikoff-Etievant M F. Immunotherapy for recurrent miscarriage. Consensus conference; July 16-17, 1993; Washington, DC.  Am J Reprod Immunol. 1994;  32 257-302
• 57 Scott J R, Branch W D, Dudley D J, Hatasaka H H. Immunotherapy for recurrent pregnancy loss: the University of Utah perspective. In: Dondero F, Johnson P Reproductive Immunology. Serono Symposium Publications. New York; Raven Press 1997: 255-257
• 58 Christiansen O B, Mathiesen O, Husth M, Lauritsen J G, Grunnet N. Placebo-controlled trial of active immunization with third party leukocytes in recurrent miscarriage.  Acta Obstet Gynecol Scand. 1994;  73 261-268
• 59 Christiansen O B, Ring M, Rosgaard A, Grunnet N, Gluud C. Association between HLA-DR1 and -DR3 antigens and unexplained repeated miscarriage.  Hum Reprod Update. 1999;  5 249-255
• 60 Christiansen O B, Andersen A-MN, Bosch E et al.. Evidence-based investigations and treatments of recurrent pregnancy loss.  Fertil Steril. 2005;  83 821-839